LexDanaLexDanabeta
Inventor

Albert Jean Robichaud

Inventor
Ringoes, NJ, US

Overview

72→
Patents
1993–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 72 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations36%
C07DHeterocyclic compounds22%
A61KPreparations for medical, dental or toiletry purposes20%
C07JSteroids20%
C07BGeneral methods of organic chemistry1%
C07CAcyclic or carbocyclic compounds1%
Y02PClimate change mitigation technologies in the production or processing of goods1%
PatentTitleYear
11,124,538Neuroactive steroids, compositions, and uses thereof202111,117,924Oxysterols and methods of use thereof202111,111,266Oxysterols and methods of use thereof202111,104,701Neuroactive steroids and methods of use thereof202111,046,728Neuroactive steroids, compositions, and uses thereof202110,870,677Compositions and methods for treating CNS disorders202010,822,37019-nor neuroactive steroids and methods of use thereof202010,781,231Oxysterols and methods of use thereof202010,774,108Compositions and methods for treating CNS disorders202010,765,685Oxysterols and methods of use thereof202010,759,828Neuroactive steroids, compositions, and uses thereof202010,752,653Oxysterols and methods of use thereof202010,745,436Neuroactive steroids, compositions, and uses thereof202010,723,758Oxysterols and methods of use thereof202010,696,712Oxysterols and methods of use thereof202010,577,390Compositions and methods for treating CNS disorders202010,435,4313,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof201910,426,837Compositions and methods for treating CNS disorders201910,391,10619-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof201910,377,79019-nor neuroactive steroids and methods of use thereof201910,342,81019-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof201910,342,809Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same201910,329,320Neuroactive steroids, compositions, and uses thereof201910,323,059Neuroactive steroids, compositions, and uses thereof201910,259,840Oxysterols and methods of use thereof201910,246,482Neuroactive steroids, compositions, and uses thereof201910,227,375Neuroactive steroids and methods of use thereof201910,201,550Oxysterols and methods of use thereof201910,172,87119-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof201910,023,60619-nor neuroactive steroids and methods of use thereof20189,725,481'19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof'20179,676,812'Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same'20179,630,986'Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same'20179,512,165'19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof'20169,365,611'19-NOR neuroactive steroids and methods of use thereof'20168,063,053'1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands'20117,935,719'N-substituted-azacyclylamines as histamine-3 antagonists'20117,820,825'N-substituted-azacyclylamines as histamine-3 antagonists'20107,803,825'Aminoalkylazole derivatives as histamine-3 antagonists'20107,790,751'Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands'20107,732,457'Amino-pyridines as inhibitors of β-secretase'20107,723,368'Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase'20107,723,329'Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands'20107,645,752'Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors'20107,592,454'Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists'20097,560,470'Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands'20097,501,421'Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands'20097,482,461'Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands'20097,452,885'Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation'20087,429,582'Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders'20087,423,158'Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase'20087,414,051'Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands'20087,256,198'Pyrimidoindolones and methods for using same'20077,238,690'Substituted heterocycle fused gamma-carbolines'20077,238,696'Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands'2007RE039680'Substituted heterocycle fused gamma-carbolines'2007RE039679'Substituted heterocycle fused gamma-carbolines'20077,183,282'Substituted heterocycle fused γ-carbolines'20077,109,339'Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists'20067,081,455'Substituted heterocycle fused gamma-carbolines'20067,071,186'Substituted heterocycle fused gamma-carbolines'20066,849,619'Substituted pyridoindoles as serotonin agonists and antagonists'20056,780,862'Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands'20046,713,471'Substituted heterocycle fused gamma-carbolines'20046,699,852'Substituted pyridoindoles as serotonin agonists and antagonists'20046,638,934'Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands'20036,552,017'Substituted heterocycle fused gamma-carbolines'20036,548,493'Substituted heterocycle fused gamma-carbolines'20035,877,191'Phenyl spiroethercycloalkyl tachykinin receptor antagonists'19995,750,549'Cycloalkyl tachykinin receptor antagonists'19985,607,936'Substituted aryl piperazines as neurokinin antagonists'19975,258,401'Cholesterol lowering compounds'1993

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1993–1998Based in Stirling, NJ, US· patent location history
1999–2007Based in Landenberg, PA, US· patent location history
2003–2007Patents assigned to BRISTOL MYERS SQUIBB PHARMA CO (10)· patent assignee history
2005–2009Patents assigned to BRISTOL MYERS SQUIBB CO (5)· patent assignee history
2005–2019Based in Ringoes, NJ, US· patent location history
2007–2009Patents assigned to WYETH CORP (9)· patent assignee history
2010–2011Patents assigned to WYETH LLC (9)· patent assignee history
2016–2021Patents assigned to SAGE THERAPEUTICS INC (35)· patent assignee history
2018–2021Based in Cambridge, MA, US· patent location history
2020–2021Based in Boston, MA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
SAGE THERAPEUTICS INC352016–2021
BRISTOL MYERS SQUIBB PHARMA CO102003–2007
WYETH CORP92007–2009
WYETH LLC92010–2011
BRISTOL MYERS SQUIBB CO52005–2009
Locations
LocationPatentsSpan
Ringoes, New Jersey, US312005–2019
Cambridge, Massachusetts, US182018–2021
Boston, Massachusetts, US112020–2021
Landenberg, Pennsylvania, US81999–2007
Stirling, New Jersey, US31993–1998